Prosensa, in Holland, receive an initial grant of 940,000 euros from the Dutch Government to support further development of preclinical compounds for the treatment of Myotonic Dystrophy, with the potential to receive additional funding up to 5 Million euros, subject to successful completion of specific milestones and an initial review in 2012.

Study showing how molecules escape from the cell nucleus  - USA
Professor Robert Singer of the Albert Einstein College of Medicine, New York publishes a paper in Nature.

For more visit: http//www.eurekalert.org/pubreleases/2010-09/aeco-nss090810.php

Results of a dose escalation trial, using a human growth factor complexed with a binding protein, over 24 weeks on 15 x DM1 patients. - USA  
Professor Charles Thornton and Dr. Richard Moxley publish a paper in the US National Library of Medicine, National Institute of Health.

For more visit: http://www.ncbi.nih.gov/pubmed/20837825

 

"Towards a therapy for Myotonic Dystrophy: hope and perspective".
A lecture in lay terms by Susan Mulders, of Prosensa Therapeutics in Lieden and an Associate of Nijmegen University, to the VSN Myotonic Dystrophy Support Group in Holland. For More Information Click Here.

‘Screening for drugs to treat myotonic dystrophy and other neuromuscular conditions’ : Professor David Brook and Dr. Javier Riveron of Nottingham University publish article in Target Research.

For more, visit: www.muscular-dystrophy.org/research

Understanding the Science of Myotonic Dystrophy and New Developments in therapies for Myotonic Dystrophy - USA. Presentations at IDMC-7 by Professor Charles Thornton of the University of Rochester and Dr. Maury Swanson of the University of Florida are published on YouTube.

To view visit: The Myotonic Dystrophy Foundation (MDF) YouTube Channel at www.myotonic.com

IDMC-7 Held in Wurzburg, Germany where representatives from the pharmaceutical industry attend for the first time. For more visit: www.idmc-7.com

Discovery of a Compound that Reverses Myotonic Dystrophy Type 1 (DM1) - USA.  A joint team from the U.S. Universities of Rochester and Oregon report that Pentamidine, when tested on genetically altered mice, counters splicing defects in RNA that lead to DM1.

For more visit: http://comm.uoregon.edu/archive/news-release/2009/11/possible-help-fight-against-muscle-wasting-disease and www.myotonic.com

Triplet,repeat,oligonucleotide,mediated,reversal of RNA toxicity in Myotonic Dystrophy- Netherlands. Susan Mulders of Nijmegen University publishes a paper in The Proceedings of the National Academy of Sciences.

For more visit: www.pnas.org and www.umcn.ne